Logo Image
News|Articles|January 7, 2019

In the Lab eNewsletter

  • Pharmaceutical Technology\'s In the Lab eNewsletter-01-09-2019
  • Volume 14
  • Issue 1

Enhanced Sterility Testing Device

The Steritest NEO device from MilliporeSigma provides safer pharmaceutical product testing through additional features.

The Steritest NEO device from MilliporeSigma provides safer pharmaceutical product testing. This fourth-generation unit includes improved ergonomics, easy-to-open accessory bags; 25-mL gradation mark for accurate pre-wetting step measurement; colored clamps to differentiate media filling; clearer labeling with colors, drawings, and barcodes for easy identification; and peel and stick labels for improved traceability.

According to the company, these improvements do not change the materials that come into contact with the tested fluid or in performance specification. The devices are supplied with certificates of quality, and the membrane and canisters undergo strict integrity and microbiological tests. 

The product was launched on Dec. 17, 2018.

Source: MilliporeSigma

Articles in this issue

over 7 years ago

Unprocessed Bulk Testing for Biopharmaceuticals

over 7 years ago

NIST Fluorescence-Based Measurement Services

almost 8 years ago

Trianni, MacroGenics Team Up for mAb R&D Platform

almost 8 years ago

New Berkeley Lights Workflow Speeds Up Drug Discovery

almost 8 years ago

New Reagents Optimize Biologics Production

almost 8 years ago

Lilly and AC Immune Sign Agreement for R&D of Potential Alzheimer’s Treatment

almost 8 years ago

Histo-Scientific Research Laboratories and Vet Path Services Merge

almost 8 years ago

FDA Answers Data Integrity Questions

almost 8 years ago

TrendMiner Updates Analytics Software

Related to this article

View more
Complying with International Pharmacopoeias
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Read more
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Read more
PharmTech Weekly Roundup—October 2, 2026
PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Read more
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Read more
Regulatory Roundup—September 2026
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Read more